Llovet JM - Search Results

1

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators. Zhu AX, et al. Among authors: llovet jm. Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18. Lancet Oncol. 2019. PMID: 30665869 Clinical Trial.

2

Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power.

Llovet JM, Bruix J, Fuster J, Castells A, Garcia-Valdecasas JC, Grande L, Franca A, Brú C, Navasa M, Ayuso MC, Solé M, Real MI, Vilana R, Rimola A, Visa J, Rodés J. Llovet JM, et al. Hepatology. 1998 Jun;27(6):1572-7. doi: 10.1002/hep.510270616. Hepatology. 1998. PMID: 9620329

3

Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution.

Bruix J, Llovet JM, Castells A, Montañá X, Brú C, Ayuso MC, Vilana R, Rodés J. Bruix J, et al. Among authors: llovet jm. Hepatology. 1998 Jun;27(6):1578-83. doi: 10.1002/hep.510270617. Hepatology. 1998. PMID: 9620330 Clinical Trial.

4

Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Llovet JM, Brú C, Bruix J. Llovet JM, et al. Semin Liver Dis. 1999;19(3):329-38. doi: 10.1055/s-2007-1007122. Semin Liver Dis. 1999. PMID: 10518312

5

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma.

Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, Ayuso C, Vargas V, Rodés J, Bruix J. Llovet JM, et al. Hepatology. 2000 Jan;31(1):54-8. doi: 10.1002/hep.510310111. Hepatology. 2000. PMID: 10613728 Clinical Trial.

6

Locoregional treatments for hepatocellular carcinoma.

Bruix J, Llovet JM. Bruix J, et al. Among authors: llovet jm. Baillieres Best Pract Res Clin Gastroenterol. 1999 Dec;13(4):611-22. doi: 10.1053/bega.1999.0051. Baillieres Best Pract Res Clin Gastroenterol. 1999. PMID: 10654923 Review.

7

Nonsurgical treatment of hepatocellular carcinoma.

Llovet JM, Sala M, Bruix J. Llovet JM, et al. Liver Transpl. 2000 Nov;6(6 Suppl 2):S11-5. doi: 10.1053/jlts.2000.18684. Liver Transpl. 2000. PMID: 11084079 Free article. Review.

8

Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma.

Llovet JM, Vilana R, Brú C, Bianchi L, Salmeron JM, Boix L, Ganau S, Sala M, Pagès M, Ayuso C, Solé M, Rodés J, Bruix J; Barcelona Clínic Liver Cancer (BCLC) Group. Llovet JM, et al. Hepatology. 2001 May;33(5):1124-9. doi: 10.1053/jhep.2001.24233. Hepatology. 2001. PMID: 11343240

9

Prognosis of hepatocellular carcinoma.

Llovet JM, Fuster J, Bruix J. Llovet JM, et al. Hepatogastroenterology. 2002 Jan-Feb;49(43):7-11. Hepatogastroenterology. 2002. PMID: 11941987 Review.

10

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.

Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J; Barcelona Liver Cancer Group. Llovet JM, et al. Lancet. 2002 May 18;359(9319):1734-9. doi: 10.1016/S0140-6736(02)08649-X. Lancet. 2002. PMID: 12049862 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

356 results

Search Page